Univariable analysis | Multivariable analysis | |||||
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
Age | 0.984 | 0.967–1.002 | 0.078 | 0.988 | 0.929–1.051 | 0.709 |
Sex male | 0.817 | 0.518–1.290 | 0.386 | – | – | – |
Current smoker | 0.745 | 0.419–1.324 | 0.315 | – | – | – |
Pack-year | 0.991 | 0.981–1.002 | 0.097 | 1.022 | 0.999–1.047 | 0.064 |
N stage ≥1 | 1.992 | 1.192–3.322 | 0.009 | 3.472 | 1.160–10.417 | 0.026 |
Extracranial stage IV | 3.760 | 2.249–6.287 | <0.001 | 2.904 | 0.918–9.190 | 0.070 |
Adenocarcinoma | 0.939 | 0.600–1.470 | 0.783 | – | – | – |
Squamous carcinoma | 1.195 | 0.643–2.222 | 0.574 | – | – | – |
Large-cell carcinoma | 0.640 | 0.201–2.039 | 0.450 | – | – | – |
Poorly differentiated carcinoma | 1.265 | 0.731–2.191 | 0.401 | – | – | – |
EGFR mutation | 1.736 | 1.021–2.954 | 0.042 | 5.670 | 1.996–16.104 | 0.001 |
ALK amplification | 1.230 | 0.444–3.410 | 0.690 | – | – | – |
PD-L1 expression >10% | 0.474 | 0.250–0.898 | 0.022 | 0.658 | 0.257–1.686 | 0.384 |
CCRT | 0.323 | 0.102–1.022 | 0.055 | – | – | – |
Conventional chemotherapy | 1.507 | 0.848–2.680 | 0.163 | – | – | – |
Single lesion | 0.368 | 0.217–0.624 | <0.001 | 0.358 | 0.108–1.179 | 0.091 |
Rim enhancement | 2.668 | 1.707–4.171 | <0.001 | 1.868 | 0.768–4.542 | 0.168 |
Initial size mm | 1.215 | 1.106–1.334 | <0.001 | 1.436 | 1.170–1.763 | <0.001 |
Multivariable analysis was conducted with the variables with p<0.1 in the univariable analyses. EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; PD-L1: programmed death-ligand 1; CCRT: concurrent chemoradiation therapy.